BR112019007856A8 - Composição, e, método para remover anticorpos de tirosina sulfatada ou fragmentos de ligação a antígeno dos mesmos - Google Patents

Composição, e, método para remover anticorpos de tirosina sulfatada ou fragmentos de ligação a antígeno dos mesmos

Info

Publication number
BR112019007856A8
BR112019007856A8 BR112019007856A BR112019007856A BR112019007856A8 BR 112019007856 A8 BR112019007856 A8 BR 112019007856A8 BR 112019007856 A BR112019007856 A BR 112019007856A BR 112019007856 A BR112019007856 A BR 112019007856A BR 112019007856 A8 BR112019007856 A8 BR 112019007856A8
Authority
BR
Brazil
Prior art keywords
antigen
binding fragments
composition
removing sulfate
tyrosine antibodies
Prior art date
Application number
BR112019007856A
Other languages
English (en)
Other versions
BR112019007856A2 (pt
Inventor
Zhao Jia
RIOS Sandra
Dukleska Schussler Svetlana
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112019007856A2 publication Critical patent/BR112019007856A2/pt
Publication of BR112019007856A8 publication Critical patent/BR112019007856A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J47/00—Ion-exchange processes in general; Apparatus therefor
    • B01J47/02—Column or bed processes
    • B01J47/026—Column or bed processes using columns or beds of different ion exchange materials in series
    • B01J47/028—Column or bed processes using columns or beds of different ion exchange materials in series with alternately arranged cationic and anionic exchangers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A presente invenção refere-se a composições de anticorpos purificados e de fragmentos de ligação a antígeno faltando tirosina sulfatada sobre um ou mais resíduos tirosina nas cadeias de imunoglobulina. Os métodos de purificação para remover variantes de tirosina sulfatada a partir das composições de anticorpos e de fragmentos de ligação a antígeno são também providos.
BR112019007856A 2016-10-28 2017-10-26 Composição, e, método para remover anticorpos de tirosina sulfatada ou fragmentos de ligação a antígeno dos mesmos BR112019007856A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662414209P 2016-10-28 2016-10-28
PCT/US2017/058386 WO2018081329A1 (en) 2016-10-28 2017-10-26 Purification process for removal of tyrosine sulfation antibody variants; purified compositions

Publications (2)

Publication Number Publication Date
BR112019007856A2 BR112019007856A2 (pt) 2019-10-01
BR112019007856A8 true BR112019007856A8 (pt) 2023-04-11

Family

ID=62024014

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007856A BR112019007856A8 (pt) 2016-10-28 2017-10-26 Composição, e, método para remover anticorpos de tirosina sulfatada ou fragmentos de ligação a antígeno dos mesmos

Country Status (10)

Country Link
US (1) US20200123251A1 (pt)
EP (1) EP3532046A4 (pt)
JP (2) JP7229157B2 (pt)
KR (1) KR102617873B1 (pt)
CN (1) CN109963560A (pt)
AU (1) AU2017347809A1 (pt)
BR (1) BR112019007856A8 (pt)
CA (1) CA3039667A1 (pt)
MX (1) MX2019004957A (pt)
WO (1) WO2018081329A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072769A2 (en) * 2000-03-27 2001-10-04 Genetics Institute, Llc Methods for purifying highly anionic proteins
US7488481B2 (en) * 2003-02-10 2009-02-10 The Brigham And Women's Hospital, Inc. Polypeptides derived from anti-HIV-1 gp120 antibodies that abrogate gp120 binding to CCR5
US20070298034A9 (en) * 2005-12-09 2007-12-27 Angela Widom Sulfotyrosine specific antibodies and uses therefor
JP6345184B2 (ja) * 2012-10-30 2018-06-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２段階接線流限外濾過を使用するポリペプチドの精製
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3247718B1 (en) * 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
JP2022546922A (ja) * 2019-07-30 2022-11-10 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｐｄ－１／ｌａｇ３／ｔｉｇｉｔ三重特異性抗体および抗ｐｄ－１／ｌａｇ３二重特異性抗体

Also Published As

Publication number Publication date
JP2023011753A (ja) 2023-01-24
EP3532046A1 (en) 2019-09-04
MX2019004957A (es) 2019-06-24
US20200123251A1 (en) 2020-04-23
AU2017347809A1 (en) 2019-05-09
EP3532046A4 (en) 2020-12-30
WO2018081329A1 (en) 2018-05-03
RU2019116216A3 (pt) 2021-04-28
KR20190067898A (ko) 2019-06-17
CA3039667A1 (en) 2018-05-03
JP2019535676A (ja) 2019-12-12
JP7229157B2 (ja) 2023-02-27
KR102617873B1 (ko) 2023-12-22
CN109963560A (zh) 2019-07-02
RU2019116216A (ru) 2020-11-30
BR112019007856A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
BR112018075516A2 (pt) purificação de anticorpos multiespecíficos
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201990243A1 (ru) Новые антитела, которые специфически связываются с эпитопами вируса зика, и их применения
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
BR112017010094A2 (pt) anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
CU20170169A7 (es) Anticuerpos de factor xi
PE20170665A1 (es) Anticuerpos anti-tau humanizados
PE20180499A1 (es) Anticuerpos de union a tau
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PE20180481A1 (es) Anticuerpos de union a tau
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
AR087601A1 (es) Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
EA202090559A1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
BR112017007877A2 (pt) anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)